Cronos Group Inc (CRON)

Sep 26, 2026

Cronos Group (NASDAQ:CRON) hosted its first-ever strategy day, emphasizing an international growth strategy supported by a strong balance sheet. The company extended the timeline for a planned acquisition of a Dutch cannabis grower and launched new edible products. Cronos aims to differentiate itself through measured international expansion, product innovation, and its robust financial position within the competitive cannabis industry.

Sep 24, 2026

Cronos Group Inc. (TSX:CRON) is gaining market attention due to its involvement in consumer-linked cannabis names experiencing a mixed trading session. The company operates in the cannabis products and brands sector, making its performance relevant to specific internal developments rather than solely broad market movements. While the S&P/TSX Composite Index provides general Canadian market context, the company's story is primarily driven by its unique operating facts and future corporate disclosures.

Sep 19, 2026

Cronos Group (TSX:CRON) is gaining renewed attention due to its expanding international strategy and steady stock momentum. While a narrative-based valuation model suggests the stock is modestly above fair value, a discounted cash flow model indicates it might be significantly undervalued. The company's future hinges on regulatory developments, operational cost reductions, and successful international expansion.

Sep 15, 2026

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) will host its first Investor Day on Thursday, September 24, 2026, at its Cronos GrowCo facility in Kingsville, Ontario. The event will feature a fireside chat with CEO Mike Gorenstein and Cronos GrowCo CEO Bert Mucci, presentations from executive leadership, and a tour of the 1.3 million square foot greenhouse for in-person attendees. A webcast of the session will also be available for those unable to attend in person.

Sep 12, 2026

Cronos Group Inc. (NASDAQ:CRON) has received an average "Hold" rating from five brokerages, with three recommending a hold and two a buy. The average 12-month price target is $2.30, and recent analyst sentiment has seen downgrades from "Buy" to "Hold" by Weiss Ratings and Wall Street Zen. The company recently reported stronger-than-expected quarterly results, with earnings per share of $0.09 against a consensus estimate of $0.01 and revenue of $53.01 million compared to an expected $44.20 million.